Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes.
about
Role of implants in the treatment of diabetic macular edema: focus on the dexamethasone intravitreal implantINTRAVITREAL CORTICOSTEROIDS IN DIABETIC MACULAR EDEMA: PHARMACOKINETIC CONSIDERATIONSPerspective on the role of Ozurdex (dexamethasone intravitreal implant) in the management of diabetic macular oedemaDexamethasone intravitreal implant in the treatment of diabetic macular edemaPharmacokinetics and retinal toxicity of various doses of intravitreal triamcinolone acetonide in rabbits.Efficacy of 0.2 μg/day fluocinolone acetonide implant (ILUVIEN) in eyes with diabetic macular edema and prior vitrectomyUpcoming therapeutic advances in diabetic macular edema: an intravitreal dexamethasone drug delivery system.Pharmacokinetics, electrophysiological, and morphological effects of the intravitreal injection of mycophenolic acid in rabbitsDisplacement of submacular hemorrhage associated with age-related macular degeneration using vitrectomy and submacular tPA injection followed by intravitreal ranibizumabRETRACTED: Influence of choroidal neovascularization and biodegradable polymeric particle size on transscleral sustained delivery of triamcinolone acetonide.Pathophysiology and treatment of diabetic retinopathy.Recent advances in ophthalmic drug delivery.Impact on intraocular pressure after 20-mg decanted triamcinolone acetonide (kenalog) injection when using prophylactic antiglaucoma therapy.Contribution of saccadic motion to intravitreal drug transport: theoretical analysis.Progression to macula-off tractional retinal detachment after a contralateral intraoperative intravitreal bevacizumab injection for proliferative diabetic retinopathy.Pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbitsRANIBIZUMAB PLUS PROMPT OR DEFERRED LASER FOR DIABETIC MACULAR EDEMA IN EYES WITH VITRECTOMY BEFORE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.Triamcinolone reduces neovascularization, capillary density and IGF-1 receptor phosphorylation in a model of oxygen-induced retinopathy.Pars plana vitrectomy with intravitreal triamcinolone: effect on uveitic cystoid macular oedema and treatment limitations.Long-term evaluation of dexamethasone intravitreal implant in vitrectomized and non-vitrectomized eyes with macular edema secondary to non-infectious uveitisComplications of intravitreal triamcinolone acetonide for macular edema and predictive factors for intraocular pressure elevationSustained-release intravitreal liquid drug delivery using triamcinolone acetonide for cystoid macular edema in retinal vein occlusion.Intravitreal triamcinolone acetonide injection at the time of pars plana vitrectomy for retained lens material.Pharmacokinetics of intravitreally injected bevacizumab in vitrectomized eyes.Twelve-Month Follow-Up of Dexamethasone Implants for Macular Edema from Various Diseases in Vitrectomized and Nonvitrectomized Eyes.Pharmacokinetics of bevacizumab after topical and intravitreal administration in human eyes.Long-term intraocular pressure changes after vitrectomy for epiretinal membrane and macular holeThe dexamethasone drug delivery system: indications and evidence.Pharmacokinetics of triamcinolone acetonide for the treatment of macular edema.Inflammation and macular oedema after pars plana vitrectomy.Novel Intraocular Therapy in Non-infectious Uveitis of the Posterior Segment of the Eye.Widening use of dexamethasone implant for the treatment of macular edemaCOMBINED VITRECTOMY AND INTRAVITREAL DEXAMETHASONE (OZURDEX) SUSTAINED-RELEASE IMPLANTIntravitreal ranibizumab for diabetic macular oedema in previously vitrectomized eyes.Treatment of refractory uveitic macular edema with dexamethasone intravitreal implants in a pediatric patient with bilateral granulomatous idiopathic panuveitis: a case report.Novel pentablock copolymer (PLA-PCL-PEG-PCL-PLA) based nanoparticles for controlled drug delivery: Effect of copolymer compositions on the crystallinity of copolymers and in vitro drug release profile from nanoparticles.The ocular toxicity and pharmacokinetics of simvastatin following intravitreal injection in mice.Ocular hypertension after intravitreal triamcinolone with vitrectomy and phacoemulsificationManagement of macular edema secondary to branch retinal vein occlusion in an eye with prior vitrectomy and lensectomyIntraoperative intravitreal triamcinolone decreases macular edema after vitrectomy with phacoemulsification.
P2860
Q26775853-0D8DEC06-25CA-4E0A-8064-E7665E004285Q26782198-1FFA8A6F-07F9-49A5-AD61-637B33A47CF4Q26786012-01CE0129-E56C-44C5-BF12-E74BDFECA47EQ26799423-682F8208-4640-453D-A043-720B7946EE31Q33614276-A1A2C28A-5153-4196-AD72-76EE4A84CAAAQ33705718-1BF5A903-81E7-4E9C-A5E4-A7796EE9E176Q33790255-AF9A89C4-9FF5-45E8-B643-1AC863CE6033Q33820065-B0A78B3D-6C5B-4EEA-B9C5-949FD570938FQ34019693-21F464FF-69C1-4F28-A25D-D875602A8D8FQ34283230-62A16ED7-AC98-4F78-B96B-0AC0299B6DA1Q34528134-B7736193-6CE4-4F10-B3F7-9D14545E0567Q34636338-A1478D1D-2EA1-438C-9690-C8E104637725Q34771834-46016EDC-34C4-4F74-AC97-60D15BD7E0A1Q34778859-74260250-51FB-4A38-94C3-D49D646260BDQ34952041-52FBCAEF-A2FB-44A4-B2A7-CFB554AC5C03Q35015882-6AF4254D-8F15-4829-A84B-C91D749C0943Q35649867-8CDC6BCA-24F9-4B7A-98DB-7ED4AD962F26Q35688128-120594F7-A134-4490-91C3-DD692E264E06Q35763093-87032801-56F3-46ED-8293-8A011D44D072Q35863034-CBE79725-27A7-4A9B-8CF7-4FD05D74CF87Q36490459-2C20604D-E91A-4126-BCFC-733828239B98Q37075647-45AEF6CA-58DB-4450-9B53-692818291661Q37128284-9B6CB810-C30A-4396-BEC3-A857BD91B0CEQ37133086-2C481BEA-0B6C-4582-BEB4-284F3321300FQ37303225-69DA2C80-B99B-4A13-884E-672E0D59D072Q37549985-FFDC6DE3-0724-4482-9E9D-93C86DF7D369Q37610845-61B9CAA8-DD7C-4DC9-9761-F900798BC5B6Q37865422-6C0C5E20-847B-4A35-8B65-38FA181DED4AQ37905833-9666AC9F-A57F-40EF-AB0C-2506A58A0CA3Q38167310-BAF2FF08-ED2F-4E43-9EE1-FCBCD7272FD6Q38211433-B3058A9F-2803-42A1-B8FB-726B82768236Q38599000-9E09C483-7E1E-4A25-B373-05FF5B591D23Q38826431-103B9BA6-BBB9-48AD-A10B-962DAA739AF2Q38912755-AF16DF45-49DA-4231-BEE9-F1EE9373612CQ39457673-44E76FB1-5510-42A3-85AB-35DECF31E9C2Q40010634-50F7D8D4-272B-4C68-9EB7-AA015B0AA5E9Q41697545-A4B1CD2B-89E9-49FD-BD12-AF0A636CF232Q41894162-EC7B1E8B-BF83-4312-9AA8-5C143DD51B9BQ42116625-63E913CA-BE61-4AF5-886A-ED4345B0C8CDQ42321602-82943483-A4E3-4354-B351-82C909DBFD5F
P2860
Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Difference in clearance of int ...... zed and nonvitrectomized eyes.
@en
type
label
Difference in clearance of int ...... zed and nonvitrectomized eyes.
@en
prefLabel
Difference in clearance of int ...... zed and nonvitrectomized eyes.
@en
P2093
P1433
P1476
Difference in clearance of int ...... zed and nonvitrectomized eyes.
@en
P2093
Hee-Seung Chin
Jung-Hyub Oh
Tae-Sung Park
Yeon-Sung Moon
P304
P356
10.1097/00006982-200507000-00002
P577
2005-07-01T00:00:00Z